Drug intelligence / Profile preview

COEC

Development stage: Unknown
Modality: Inhalation Devices → Device-based Delivery → Drug Delivery Systems, Small Molecules, Implantable Devices → Device-based Delivery → Drug Delivery Systems, Transdermal Patches → Device-based Delivery → Drug Delivery Systems
Administration: Oral

Overview

COEC is a combination product consisting of extracts from *Cornus officinalis* (CO) and *Ribes fasciculatum* (RF). It is developed as an anti-obesity agent, demonstrated to significantly reduce body fat percentage and mass in overweight women. Administered orally in tablet form, COEC is considered a protective functional agent for obesity.

Other names: Cornus officinalis and Ribes fasciculatum mixture

Beyond the preview

Go deeper on COEC.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on COEC.

Explore the full profile